FIELD: pharmacology.
SUBSTANCE: invention relates to a new co-crystalline form of isoniazid with 4-aminobenzoic acid, wherein the molar ratio of isoniazid to 4-aminobenzoic acid is 1:1, having an endothermic peak of 122 to 128°C according to the measurement using differential scanning calorimetry (DSC analysis) and having peaks at 2θ(°) 7.5, 11.7, 12.2, 14.5, 15.8, 16.9, 21.5, 28.3 based on the data of X-ray powder diffraction measurement.
EFFECT: preparation of a co-crystalline form of isoniazid suitable for application in the pharmaceutical industry as a component of a pharmaceutical preparation for treatment of tuberculosis, with increased physical and mental loads, fatigue, with simultaneous increase of solubility.
7 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
| COCRYSTALLINE FORM OF FENBUFEN | 2012 |
|
RU2521572C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
| CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE WITH SALICYLIC ACID | 2013 |
|
RU2539350C1 |
| COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
| CO-CRYSTALLINE FORM OF 1-[(5-PARA-METHYL-META-CHLORO-PHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2019 |
|
RU2721335C1 |
| CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
| COCRYSTALLINE FORM OF 1-[5-(4-CHLOROPHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2018 |
|
RU2712443C1 |
| HYDRATE OF CIPROFLOXACIN SALT WITH 4-AMINOBENZOIC ACID | 2019 |
|
RU2706351C1 |
